ReliBeta® (Interferon beta-1a) - LifeSciences
- AbcixiRel® (Abciximab)
- AdaliRel® (Adalimumab)
- BevaciRel® (Bevacizumab)
- ChorioRel® (r-hCG)
- DarbeRel® (Darbepoetin)
- EtanerRel® (Etanercept)
- FostiRel® (FSH)
- Infimab® (Infliximab)
- MIRel® (Reteplase)
- Peg-ReliGrast® (Peg-GCSF)
- ReliBeta® (Interferon beta-1a)
- ReliFeron® (Interferon α)
- ReliGrast® (GCSF)
- ReliPoietin® (Erythropoietin)
- RituxiRel® (Rituximab)
- SomatoRel® (r-hGH)
- TenecteRel® (Tenecteplase)
- TrastuRel® (Trastuzumab)
Interferons are a family of naturally occurring proteins and glycoproteins that are produced by eukaryotic cells in response to viral infection and other biological inducers. Interferon beta, a member of interferon family, is produced by various cell types including fibroblasts and macrophages.
Recombinant interferon beta-1a is a glycosylated protein with a single N-linked glycosylation site, similar to the natural interferon beta-1a.
ReliBeta (recombinant Interferon beta-1a) is a 166 amino acid glycoprotein with a molecular weight of approximately 22 kDa. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of ReliBeta® is identical to that of natural human interferon beta.
ReliBeta is indicated for the treatment of patients with relapsing multiple sclerosis.
ReliBeta is a sterile, preservative-free, clear colourless liquid for intramuscular injection.
ReliBeta is available as a ready for use pre-filled glass syringe with 0.5 ml fill volume. Each 0.5 ml in a pre-filled glass syringe contains 30 µg of interferon-beta-1a in sodium acetate aqueous buffer containing L-arginine hydrochloride and polysorbate 20.